The decision began with one Phase 3 trial, which Merck discontinued after reviewing results. The company later assessed additional data and stopped two other Phase 3 trials of nemtabrutinib.
The drug had been under evaluation for patients with chronic lymphocytic leukemia, small lymphocytic leukemia and other hematologic malignancies. Merck did not provide further details in its announcement.

Comments (0)
No comments yet. Be the first!